135 related articles for article (PubMed ID: 13656582)
41. Scleromyxedema: successful treatment of cutaneous and neurologic symptoms.
Nieves DS; Bondi EE; Wallmark J; Raps EC; Seykora JT
Cutis; 2000 Feb; 65(2):89-92. PubMed ID: 10696560
[TBL] [Abstract][Full Text] [Related]
42. Cutaneous focal mucinosis associated with reticular erythematous mucinosis and scleromyxedema.
Rongioletti F; Amantea A; Balus L; Rebora A
J Am Acad Dermatol; 1991 Apr; 24(4):656-7. PubMed ID: 2033150
[No Abstract] [Full Text] [Related]
43. [Scleromyxedema Arndt-Gottron and plasmacytoma].
Proppe A; Becker V; Hardmeier T
Hautarzt; 1969 Feb; 20(2):53-9. PubMed ID: 5359061
[No Abstract] [Full Text] [Related]
44. Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients.
Sansbury JC; Cocuroccia B; Jorizzo JL; Gubinelli E; Gisondi P; Girolomoni G
J Am Acad Dermatol; 2004 Jul; 51(1):126-31. PubMed ID: 15243538
[TBL] [Abstract][Full Text] [Related]
45. Early onset of scleromyxedema Arndt-Gottron associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins.
Kefi A; Jaziri F; Ben Abdelghani K; Turki S
Clin Case Rep; 2022 Aug; 10(8):e6122. PubMed ID: 35937020
[TBL] [Abstract][Full Text] [Related]
46. Fatal scleromyxedema: report of a case and review of the literature.
Godby A; Bergstresser PR; Chaker B; Pandya AG
J Am Acad Dermatol; 1998 Feb; 38(2 Pt 2):289-94. PubMed ID: 9486700
[TBL] [Abstract][Full Text] [Related]
47. Papular mucinosis (scleromyxoedema of Arndt-Gottron) associated with paraprotein IgG kappa type.
Brigden WD
Proc R Soc Med; 1974 Mar; 67(3):200-1. PubMed ID: 4820816
[No Abstract] [Full Text] [Related]
48. [Dermato-neuro syndrome-an acute and life-threatening complication of scleromyxedema Arndt-Gottron].
Linse KP; Enk A; Hoffmann J
Dermatologie (Heidelb); 2023 Aug; 74(8):618-620. PubMed ID: 37284981
[TBL] [Abstract][Full Text] [Related]
49. Successful treatment of intractable scleromyxedema with cyclosporin A.
Saigoh S; Tashiro A; Fujita S; Matsui M; Shibata S; Takeshita H; Duan H; Moroi Y; Urabe K; Koga T; Furue M
Dermatology; 2003; 207(4):410-1. PubMed ID: 14657639
[No Abstract] [Full Text] [Related]
50. [Lichen myxoedematosus with consecutive Arndt-Gottron scleromyxedema in paraproteinemia, seroactive toxoplasmosis and myocardial hypoxia].
Pambor M; Höfs W
Arch Klin Exp Dermatol; 1968; 232(2):127-37. PubMed ID: 5671569
[No Abstract] [Full Text] [Related]
51. [Scleromyxedema: immunosuppressive therapy with cyclophosphamide].
Aberer W; Wolff K
Hautarzt; 1988 May; 39(5):277-80. PubMed ID: 3403262
[TBL] [Abstract][Full Text] [Related]
52. [Eye manifestations during Arndt-Gottron disease (papullous mucinosis)].
Vignat MJ; Biard L; Terzian M; Perdriel G
Bull Soc Ophtalmol Fr; 1974 Apr; 74(4):389-93. PubMed ID: 4468136
[No Abstract] [Full Text] [Related]
53. [Scleromyxedema: ultrastructural study].
Gómez-Díez S; Del Brío-León MA; Coto P; Pérez-Oliva N; Riera-Rovira P
Actas Dermosifiliogr; 2005 Nov; 96(9):619-22. PubMed ID: 16476310
[TBL] [Abstract][Full Text] [Related]
54. [Scleromyedema with special hyperkeratosis lesions and calcifications].
Ferrándiz C; Lecha M; Aguadé JP
Med Cutan Ibero Lat Am; 1975; 3(5):353-9. PubMed ID: 1241787
[TBL] [Abstract][Full Text] [Related]
55. Lichen myxedematosus (papular mucinosis Dalton and Sidell); report of an additional case.
ZAKON SJ; JOHNSON JH; GRINVALSKY H
AMA Arch Derm; 1959 May; 79(5):519-23. PubMed ID: 13636442
[No Abstract] [Full Text] [Related]
56. [Papular mucinosis with a scleroderma-like state of both legs (sclero-myxedema?)].
Témime P
Bull Soc Fr Dermatol Syphiligr; 1967; 74(5):581-2. PubMed ID: 5587888
[No Abstract] [Full Text] [Related]
57. [Scleromyxedema with laryngeal changes. Beneficial results of the treatment with mucopolysaccharidases].
Cosgarea R; Cosgarea M; Turcu T
Ann Dermatol Venereol; 1994; 121(2):159-61. PubMed ID: 7979029
[TBL] [Abstract][Full Text] [Related]
58. Diseases of the dermis. General considerations.
Achten G
Arch Belg Dermatol Syphiligr; 1972; 28(1):1-13. PubMed ID: 4656304
[No Abstract] [Full Text] [Related]
59. [Significance of histopathologic analysis of skin lesions in scleromyxedema. Light microscopy, electron microscopy, immunohistochemistry and immunofluorescence microscopy].
Krajnc I; Vizjak A; Hvala A; Jurcic V; Rozman B
Acta Med Austriaca; 1998; 25(3):109-12. PubMed ID: 9816405
[TBL] [Abstract][Full Text] [Related]
60. [Papulous mucinosis or scleromyxedema. Etiopathogenic, diagnostic and therapeutic aspects].
Pérez-García R; Olivas E; Vascónez F; Barril G; Anaya F; Valderrábano F
Rev Clin Esp; 1980 Dec; 159(5):313-5. PubMed ID: 7012958
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
